Neumora Therapeutics Closes $349.6M Public Offering
Ticker: NMRA · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, public-offering, healthcare
TL;DR
Neumora just raised $349.6M from a stock offering. Big cash infusion for drug development.
AI Summary
On April 15, 2024, Neumora Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully sold 21,850,000 shares of common stock at a price of $16.00 per share, resulting in gross proceeds of approximately $349.6 million before deducting underwriting discounts and commissions and other offering expenses. This offering was completed on April 15, 2024.
Why It Matters
This successful capital raise provides Neumora Therapeutics with significant funding, which can be used to advance its drug development pipeline and potentially accelerate the timeline for bringing new therapies to market.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company is still in the development phase, and the success of its drug candidates carries inherent risks.
Key Numbers
- $349.6M — Gross Proceeds (Raised from the public offering)
- 21.85M — Shares Sold (In the underwritten public offering)
- $16.00 — Price Per Share (For the common stock offering)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- April 15, 2024 (date) — Closing date of the offering
- $349.6 million (dollar_amount) — Gross proceeds from the offering
- 21,850,000 (number) — Number of shares sold
- $16.00 (dollar_amount) — Price per share
FAQ
What was the total amount of gross proceeds from Neumora Therapeutics' public offering?
The total gross proceeds were approximately $349.6 million.
On what date did Neumora Therapeutics announce the closing of its public offering?
The closing of the offering was announced on April 15, 2024.
How many shares of common stock did Neumora Therapeutics sell in the offering?
Neumora Therapeutics sold 21,850,000 shares of common stock.
At what price per share was the common stock offered?
The common stock was offered at a price of $16.00 per share.
What deductions will be made from the gross proceeds?
Gross proceeds will be reduced by underwriting discounts and commissions, and other offering expenses.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-15 06:46:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
Filing Documents
- d805556d8k.htm (8-K) — 22KB
- 0001193125-24-095472.txt ( ) — 144KB
- nmra-20240415.xsd (EX-101.SCH) — 3KB
- nmra-20240415_lab.xml (EX-101.LAB) — 18KB
- nmra-20240415_pre.xml (EX-101.PRE) — 11KB
- d805556d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: April 15, 2024 By: /s/ Joshua Pinto Joshua Pinto Chief Financial Officer